Viking Therapeutics Shares Drop 1.96%, Q1 EPS Forecast at -$1.01
Viking Therapeutics closed at $31.51, down 1.96% from the prior session, underperforming the S&P 500’s 0.57% decline while shares have climbed 8.73% over the past month. Analysts forecast Q1 EPS of -$1.01 (down 146.34% y/y), full-year EPS of -$4.09 (down 28.21% y/y) and flat revenue.
1. Stock Performance
Viking Therapeutics closed at $31.51, down 1.96% from the previous session, underperforming the S&P 500’s 0.57% decline while the Dow fell 1.61% and the Nasdaq 0.26%. Over the past month, shares have gained 8.73%, versus a 0.06% rise in the Medical sector and a 0.15% drop in the S&P 500.
2. Earnings Outlook
Analysts project first-quarter EPS of -$1.01, a 146.34% year-over-year decline, with full-year EPS forecast at -$4.09 (down 28.21% y/y) and revenue expected at $0 million (flat y/y). These metrics highlight continued challenges in driving profitability and revenue growth.
3. Estimate Revisions and Rating
Consensus EPS estimates for the company declined by 5.44% over the past month, prompting a neutral Hold rating. This shift indicates analysts have moderated expectations based on recent operational trends.
4. Industry Position
The Medical–Biomedical and Genetics industry group ranks in the bottom 46% of over 250 industries by average analyst ratings. This middling sector competitiveness may weigh on investor sentiment toward Viking Therapeutics and similar biotech firms.